

## Allogenic Stem Cell Transplant for A Rare Case of CERC1 Mutation Presenting as Congenital Neutropenia

Shilpa Prabhu KS\*, Nataraj, Bharat Ram, Karthick RG and Sharat Damodar

Department of Hematology and Stem cell transplant, Mazumdar Shaw Medical Center, Narayana Hrudayalaya Limited, Bengaluru, Karnataka, India

\*Corresponding author: Shilpa Prabhu, MD, DNB (Hematology) Junior consultant, Department of Hematology Mazumdar Shaw Medical Center, Narayana Health City, Bengaluru - 560099, Karnataka, India, Tel: +91 9945642385, E-mail: shilpasgp@gmail.com

Received Date: August 07, 2021 Accepted Date: September 07, 2021 Published Date: September 09, 2021

Citation: Shilpa Prabhu KS (2021) Allogenic Stem Cell Transplant for A Rare Case of CERC1 Mutation Presenting as Congenital Neutropenia. Ann Immunol Cell Biol 8: 1-4.

### Abstract

CERC1 mutation is inherited as an autosomal recessive disorder. A loss of function mutation causes ADA2 deficiency and is characterized by vasculopathy, immunodeficiency, and neutropenia. It is also associated with variable immunodeficiency phenotypes such as low or high Immunoglobulin levels, in particular, selective IgM deficiency, high IgG levels, pan-hypogammaglobulinemia-like CVID (common variable immunodeficiency), and low memory B cells, red cell aplasia, and pure antibody deficiency [1,2]. Here we describe a young man with biallelic loss of function mutation in CERC1 presenting with recurrent infections since childhood with severe neutropenia and stroke.

**Keywords:** Immune Deficiency; Neutropenia; Allogenic Stem Cell Transplant; Rare Mutation; CERC1 gene

## Case Report

A 34-year-old man, born out of second-degree consanguineous marriage had a history of recurrent infections since 11 years of age. He was evaluated and found to have a low total leucocyte count with decreased neutrophils. Bone marrow evaluation showed normocellular to hypercellular with relative lymphocytosis. He was treated with intermittent filgrastim injections; however, there was a lack of adequate response. At the age of 19, he had left upper lobe pneumonia with a robust positive Mantoux test, hence he was started on antitubercular therapy, which he took for 10 months. But his cytopenia continued to worsen after antitubercular treatment. At the age of 30, he had sudden onset right-hand weakness and, on imaging, he was diagnosed to have acute infarct of the left parietal region and was treated for the same.

The prothrombotic assessment was negative.

Subsequently, in March 2019, he had recurrent fever with aphthous ulcers. Investigations again showed low total leucocyte counts with severe neutropenia (absolute neutrophil count of 150 cells/cumm). At this time, he presented to our haematology outpatient department for further evaluation. Bone marrow examination evaluation was repeated and showed normocellular marrow with myeloid maturation arrest at the metamyelocyte stage and absence of dysplasia. Bone marrow karyotyping was normal. In the absence of an apparent cause for severe neutropenia, whole-exome sequencing (WES) showed homozygous missense mutation in the CECR1 gene. He was planned for an allogeneic hematopoietic stem cell transplantation (aHSCT) given his severe disease. He had a matched sibling donor, WES on the donor was done, which showed that the donor was heterozygous for the same mutation. Donor workup was essentially normal and the patient underwent aHSCT.

Post-transplant, he had neutrophil and platelet engraftment on days +14 and +16, respectively. Unfortunately, he developed acute gut and skin graft versus host disease (GVHD) on day +35. GVHD responded to steroids, Etanercept and Ruxolitinib. From day +60, he developed gradual onset of hypertension with increasing creatinine. Peripheral smear showed thrombocytopenia and schistocytes; the possibility of TMA was kept. A renal biopsy was done, which showed thrombosis of glomeruli and renal microvasculature. ADAMTS 13 level was within normal limits. Exome sequencing to detect Complement factor mutation was also negative. He underwent

7 sessions of plasma exchange with steroids and two doses of Rituximab. However, he did not have any improvement in renal parameters, and LDH continued to increase.

He was initiated on dialysis for worsening renal functions.

At this point, the option of C5b inhibitor, Eculizumab, was considered. He was started on 900 mg Eculizumab from day 70 post transplant, weekly for 6 doses and then 1200 mg once in two weeks; he received a total of 9 doses of Eculizumab. After four doses of Eculizumab, his creatinine began to show a decreasing trend, and platelet counts improved. Gradually he could be weaned off dialysis support. At present, he is off Eculizumab therapy, and the last dose was received in April 2020. He has completed 20 months post allogeneic stem cell transplant and has been off immunosuppression over the previous 10 months. He has completed his routine vaccination and is currently doing well.

## Discussion & Conclusion:

CERC1 mutation is characterized by ADA2 deficiency. It is a monogenic form of systemic vasculopathy that presents in early childhood. Biallelic mutations are characterized by vasculopathy, immune deficiency, neutropenia, and bone marrow failure syndrome. Vasculopathy can range from livedo reticularis to polyarteritis nodosa (PAN) to life-threatening ischaemic stroke [3,4]. In this case, the patient had a stroke explained by the vasculopathy caused by the above mutation.

Belot, et al. proposed that ADA2 may act as a regulator of neutrophil activation. The deficiency of ADA2 (DADA2) results in endothelial damage via a neutrophil-driven process [5], which explains the mechanism of vasculopathy in these patients. ADA2 seemed to be involved in the balance between pro-inflammatory and anti-inflammatory monocytes; in the case of its absence, ADA2 was associated with a defect in differentiation of anti-inflammatory macrophages, upregulation of neutrophils expressed genes, and an increased secretion of pro-inflammatory cytokines leading to a pro-inflammatory state.[6] Aberrant ADA2 proteins (due to missense mutations) cause more vascular complications; whereas, the complete absence of ADA2 causes more profound cytopenias than vascular complications[7].

There was a history of repeated infections in our patient since 11 years of age; primary immunodeficiency workup

---

showed only a mild reduction in serum IgM levels with normal levels of other immunoglobulins. Serology was non-reactive.

As he had repeated episodes of fever with neutropenia, secondary causes of cytopenias, including drugs, connective tissue diseases, bone marrow evaluation for evidence of leukemia, malignancy, or myelodysplasia, were excluded.

This case demonstrates the importance of whole-exome sequencing (WES) in diagnosing the cause of idiopathic cytopenias. The common gene mutations causing congenital neutropenia are ELANE, HAX1, G6PC3, JAGN1, and WAS. In our patient, none of the mutations were detected in these genes. However, an extremely rare mutation was detected involving the exon 2 of CERC1 gene, (c278T>C) resulting in a homozygous mutation, characterized by substitution of threonine for isoleucine at codon 93. This variation lies in the adenosine /AMP deaminase N terminal domain. The affected individuals present with anemia, leucopenia, immunodeficiency, vasculitis and neurological manifestations. The compound heterozygous mutation presents with early onset stroke and vasculopathy.

CECR1/ADA mutations underlie a complex autoinflammatory syndrome, and systemic immunosuppressants, including steroids and anti-TNF agents, have been tried without clear effectiveness. Hematopoietic stem cell transplantation is an effective treatment in severe phenotypes.[6] Hence, in a patient with unexplained cytopenias, WES can aid in accurate diagnosis, classification, and treatment of these disorders.

## **Funding statement**

This study did not receive any specific fund from a government or private funding agencies.

## **Conflicts of interest**

All authors declare that there is no conflict-of-interest.

## **Ethics statement**

An informed patient consent was obtained for the academic publication.

## **Consent for publication**

All authors provided consent for publication.

## References

1. Hashem H, Egler R, Dalal J (2017) Refractory pure red cell aplasia manifesting as deficiency of adenosine deaminase 2. *J Pediatr Hematol Oncol* 39: e293–6.
2. Schepp J, Bulashevskaya A, Mannhardt-Laakmann W, Cao H, Yang F, et al. (2016) deficiency of adenosine deaminase 2 causes antibody deficiency. *J Clin Immunol* 36: 179–86.
3. Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, et al. (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. *N Engl J Med* 370: 921–31.
4. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, et al. (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. *N Engl J Med* 370: 911–20.
5. Belot A, Wassmer E, Twilt M, Lega JC, Zeef LA, et al. (2014) Mutations in CECR1 associated with a neutrophil signature in peripheral blood. *Pediatr Rheumatol Online J* 12: 44.
6. Caorsi R, Penco F, Schena F, Gattorno M (2016) Monogenic polyarteritis: the lesson of ADA2 deficiency. *Pediatr Rheumatol Online J* 14: 51.
7. Hsu AP, West RR, Calvo KR, Cuellar-Rodriguez J, Parata M, et al. (2016) Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. *J Allergy Clin Immunol* 138: 628-30.

### Submit your manuscript to a JScholar journal and benefit from:

- ¶ Convenient online submission
- ¶ Rigorous peer review
- ¶ Immediate publication on acceptance
- ¶ Open access: articles freely available online
- ¶ High visibility within the field
- ¶ Better discount for your subsequent articles

Submit your manuscript at  
<http://www.jscholaronline.org/submit-manuscript.php>